IMB Dx is a precision oncology company that strives to implement precision medicine and offers technologies for cancer diagnosis through analysis of tumor DNA in the blood. As the name IMB Dx (In My Blood Diagnostics) suggests, our expertise lies in liquid biopsy using blood. We are committed to understanding cancer with our advanced, proprietary technology. The AlphaLiquid® test aims to provide useful information to cancer patients and their families as well as medical professionals around the world. We are revolutionizing the way cancer is diagnosed, treated and monitored.
AlphaLiquid®100 is a liquid biopsy test designed for patients with advanced solid cancers. Our patented UniqSeq® technology detects minuscule amount of ctDNA(circulating tumor DNA) in the bloodstream for comprehensive genomic analysis. AlphaLiquid®100 detects the four classes of variations (SNV, INDEL, fusion, and CNV) in 106 NCCNrecommended genes associated with major cancer types. With this data, IMB Dx can provide information on appropriate therapy options and related on-going clinical trials.